United States· US:63833-925_a15c0e04-117a-434d-8b34-b664701b787f
ANDEMBRY
A garadacimab product containing garadacimab, registered in United States by CSL. The same ATC class is registered in 11 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Garadacimab is registered in 11 of 19 countries.
Countries holding a registration under ATC B06AC07 (garadacimab), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 7 of them publish a price we can compare per daily dose
Garadacimab · ATC B06AC07
11 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- GARADACIMAB
- Manufacturer
- CSL
- Country
- United States (US)
- ATC code
- B06AC07
- ATC class
- Garadacimab
- Defined daily dose
- 6.7 mg, P
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc1163833-925-01
- ndc1163833925011 SYRINGE, GLASS in 1 CARTON (63833-925-01) / 1.2 mL in 1 SYRINGE, GLASS (63833-925-20)
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Garadacimab in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaANDEMBRYCSL Behring GmbH, Marburg
- SwedenANDEMBRY 200 mg Injektionsvätska, lösning i förfylld injektionspennaCSL Behring GmbH
- IcelandAndembryCSL Behring GmbH*
- NetherlandsANDEMBRY 200 mg oplossing voor injectie in voorgevulde penCSL Behring GmbH
- PolandAndembryCSL Behring GmbH
- BelgiumAndembry 200 mgCSL Behring
- FinlandANDEMBRYCSL Behring GmbH
- IrelandANDEMBRY 200 mg solution for injection in pre-filled penCSL Behring GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Andembry
- Liechtenstein · Andembry
- Norway · Andembry
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/525b2d41-0542-4381-a51a-26180341ec3c GET /v1/drugs/525b2d41-0542-4381-a51a-26180341ec3c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "SUBCUTANEOUS",
"source": "ndc",
"strength": "200",
"substance": "GARADACIMAB",
"productndc": "63833-925",
"dosage_form": "INJECTION, SOLUTION",
"dea_schedule": null,
"strength_unit": "mg/1.2mL",
"application_number": "BLA761367",
"marketing_category": "BLA"
}See everything about garadacimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.